Proactive Investors Small cap news
Small cap companies performed well thsi week as while the FTSE 100 added less than 1%, the FTSE AIM All-Share Index climbed 1.4% during the week, while the FTSE AIM 100 advanced 1.8%
ReNeuron Group (AIM: RENE) has signed two further clinical grade stem cell manufacturing contracts with Angel Biotechnology Holdings (AIM: ABH) in support of ReNeuron's recently approved first-in-man clinical trial with its ReN001 therapy for stroke patients.
In its preliminary full-year results statement, Biocompatibles International (LSE: BII) said it has continued to make very good progress in 2009 in terms of its financial performance and progress with its strategic goals. In the twelve months ended 31 December 2009, the group demonstrated a substantial improvement in its sales performance, delivering revenue growth of 50%, ahead of the company’s expectations.
Medicsight PLC (AIM: MDST), specialised in Computer-Aided Detection (NYSEARCA:CAD) and image analysis software which assists in the early detection and diagnosis of disease, said it appointed Troy Robinson to the board as chief financial officer and company secretary with immediate effect.
Consort Medical (LSE: CSRT) said its plan to drive growth in the medium term has been progressing well and the business is set to hit its performance targets for the current year.
NCC Group (LSE: NCC) has acquired card services auditing and assurance company Meridian Services International Limited in a cash-only deal that could be worth up to £3 million.
Blacks Leisure Group (LSE: BLSA) has rejected an indicative, 62p per share cash offer for the company from Sports Direct International (LSE: SPD), calling the offer wholly inadequate. The specialist outdoor goods retailer said it intends to pursue a pre-emptive fundraising, which it considers to be in the best interest of its shareholders.
ECO Animal Health Group PLC (AIM: EAH) said ECO Animal Health Ltd has formed a joint venture with Pharmgate LLC of Ramsey, New Jersey, aimed at distributing the partners’ veterinary products in the North American livestock and poultry markets.
University IP commercialisation specialist Fusion IP (AIM: FIP) said its partner company Abcellute Holdings has gained a favourable opinion from a NHS Research Ethics Committee for its Abcellute Tissue Bank unit to operate as a Research Tissue Bank under NRES guidelines (National Research Ethics Service).
Alliance Pharma (AIM: APH) told investors that it has completed the transfer of a distribution agreement with Biovail Laboratories for the tetrabenazine drug, part of the recently acquired Cambridge Laboratories portfolio. Under the terms of the acquisition, completed in February, the product’s transfer was deferred subject to the successful transfer of the distribution deal.
Seeing Machines (AIM: SEE) landed its biggest contract to date for its DSS product suite in the mining sector, agreeing to supply it to BHP Billiton (LSE: BLT, ASX: BHP) subsidiaries BHP Navajo Coal Company and San Juan Coal Company, which are part of BHP’s Energy Coal business unit.
Through their respective notes to investors, London-based stockbrokers, FinnCap and Arbuthnot securities commented on smartFOCUS Group (AIM: STF), which earlier today reported solid results for FY 2009. In the 12-months ended 31 December 2009, the company said it continued to shift its revenue model towards ‘Software as a Service’, commonly referred to as ‘SaaS’.
NetPlay TV plc (AIM: NPT) announced that its managing director, Gavin Whyte, intends to step down from the board to explore new opportunities. Whyte has decided to establish his own mobile gaming business, but he will continue to assist NetPlay with its mobile strategy on a freelance basis.
Synchronica (AIM: SYNC) said that, as previously announced , its distribution partner for the MessagePhone low-cost device has received the first purchase orders for devices from subsidiaries of tier-1, multi-national mobile operator groups in Africa and Latin America. It has now received the first purchase order from the distributor for the Mobile Gateway email product worth US$203,000.
Medical and technology investor Amphion Innovations (AIM: AMP) and its partner companies have performed well in the full year and continued to make progress throughout 2009. In the year ended 31 December 2009, Amphion increased revenues by 22% to US$8.6m, subsequently gross profits increased almost 70% to US$5.8m.
Allenby Capital said that Plant impact (AIM: PIM), the developer of technologies that improve crop productivity, has world-class products and its sales are growing. According to the broker, increasing pressure on arable land, coupled with a consumer driven shift away from synthetic chemical agricultural products is creating a mass market, worth US$105bn, for ecologically sound alternatives.
Disclosure: The author holds no positions in the company